The Bio Report

The growing problem of antibiotic-resistant bacteria and the evolution of next-generation sequencing technology is giving rise to new approaches to combat what’s become a serious global health threat. Epibiome, which describes itself as a precision microbiome engineering company, is working to develop cocktails of bacteriophages to use in animal and human health. We spoke to Nick Conley, CEO of Epibiome, about the urgent need for new therapeutics, the renewed interest in phages, and Epibiome’s unique approach to address the problem.